Media coverage about Affymetrix (NASDAQ:AFFX) has been trending positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Affymetrix earned a coverage optimism score of 0.36 on Accern’s scale. Accern also gave news headlines about the scientific and technical instruments company an impact score of 45.4004893422767 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Affymetrix (NASDAQ AFFX) opened at 14.01 on Thursday. The company’s 50-day moving average price is $14.15 and its 200 day moving average price is $11.20. Affymetrix has a 1-year low of $8.28 and a 1-year high of $16.15.

COPYRIGHT VIOLATION WARNING: “Affymetrix (AFFX) Given News Sentiment Score of 0.36” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at

About Affymetrix

Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.

Receive News & Stock Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related stocks with our FREE daily email newsletter.